相关实验视频

Updated: Jun 5, 2025

Visualization of SARS-CoV-2 using Immuno RNA-Fluorescence In Situ Hybridization

Visualization of SARS-CoV-2 using Immuno RNA-Fluorescence In Situ Hybridization

Published on: December 23, 2020

小分子抑制SARS-CoV-2NSP14RNA盖甲基转移酶

Cindy Meyer¹, Aitor Garzia¹, Michael W Miller²

¹Laboratory for RNA Molecular Biology, The Rockefeller University, New York, NY, USA.

|December 11, 2024

概括

研究人员开发了一种新的小分子抑制剂,TDI-015051,针对SARS-CoV-2 NSP14 guanine-N7甲基转移酶. 这种抑制剂有效地减少了细胞和动物模型中的病毒复制,为抗击COVID-19和其他病毒性疾病提供了新的策略.

科学领域:

病毒学和药物发现
分子生物学
抗病毒疗法

背景情况:

严重急性呼吸道综合征冠状病毒2 (SARS-CoV-2) 导致COVID-19,需要有效的抗病毒治疗.
冠状病毒依赖关键蛋白质,如关氨酸-N7甲基转移酶 (NSP14) 进行复制和免疫规避.
现有的疫苗和疗法已经对大流行产生了影响,但新的抗病毒策略至关重要.

研究的目的:

发现和开发一种针对SARS-CoV-2 NSP14关氨-N7甲基转移酶的新型小分子抑制剂.
在体外和体内评估开发的SARS-CoV-2抑制剂的疗效.
探索针对病毒帽甲基酶作为广泛的抗病毒策略的潜力.

主要方法:

高通量查以识别SARS-CoV-2 NSP14的抑制剂.
对已识别的化合物进行热向优化,重点关注结合亲和力和抗病毒活性.
基于细胞的测定和转基因小鼠模型来评估病毒复制抑制和体内疗效.

主要成果:

鉴定并优化了一种非共价抑制剂,TDI-015051,具有高亲和力 (61 pM K_d) 和强大的抗病毒活性 (11 nM EC₅₀).
在细胞培养和小鼠模型中,TDI-015051显著抑制了SARS-CoV-2的复制.
TDI-015051的疗效与已批准的抗病毒药物尼马特利维尔相当.

结论:

TDI-015051是SARS-CoV-2 NSP14的第一类抑制剂,验证了这种酶作为治疗点.
这种开发的抑制剂对治疗COVID-19具有前景,需要进一步的临床研究.
抑制病毒帽甲基酶是一种可行的策略,适用于其他潜在的流行病毒.

更多相关视频

Using In Vitro and In-cell SHAPE to Investigate Small Molecule Induced Pre-mRNA Structural Changes

Using In Vitro and In-cell SHAPE to Investigate Small Molecule Induced Pre-mRNA Structural Changes

Published on: January 30, 2019

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

相关概念视频

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...

RNA Interference

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

Types of RNA

Types of RNA

Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...